Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bluebird bio Inc

BLUE
Current price
0.94 USD -0.05 USD (-5.04%)
Last closed 0.97 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 186 265 872 USD
Yield for 12 month -71.60 %
1Y
3Y
5Y
10Y
15Y
BLUE
21.11.2021 - 28.11.2021

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. Address: 455 Grand Union Boulevard, Somerville, MA, United States, 02145

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.16 USD

P/E ratio

Dividend Yield

Current Year

+21 726 000 USD

Last Year

+3 597 000 USD

Current Quarter

+12 392 000 USD

Last Quarter

+6 890 000 USD

Current Year

-2 190 000 USD

Last Year

-6 480 000 USD

Current Quarter

+1 437 000 USD

Last Quarter

-2 674 000 USD

Key Figures BLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -131 774 000 USD
Operating Margin TTM -683.74 %
PE Ratio
Return On Assets TTM -15.01 %
PEG Ratio 0.32
Return On Equity TTM -47.81 %
Wall Street Target Price 4.16 USD
Revenue TTM 21 726 000 USD
Book Value 2.08 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 17353.5 %
Dividend Yield
Gross Profit TTM -247 244 000 USD
Earnings per share -0.63 USD
Diluted Eps TTM -0.63 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BLUE

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1544:1000
Payout Ratio
Last Split Date 05.11.2021
Dividend Date

Stock Valuation BLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 15.8022
Price Sales TTM 9.7586
Enterprise Value EBITDA -2.6054
Price Book MRQ 0.9612

Financials BLUE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BLUE

For 52 weeks

0.85 USD 5.53 USD
50 Day MA 1.1 USD
Shares Short Prior Month 31 857 935
200 Day MA 2.18 USD
Short Ratio 4.25
Shares Short 31 599 109
Short Percent 17.51 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds


S

SX7EEX

14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics